Skip to main content

Advertisement

SpringerLink
Log in

Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Kleffner I, Dörr J, Ringelstein M et al (2016) Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry 87:1287–1295. https://doi.org/10.1136/jnnp-2016-314295

    Article  PubMed  Google Scholar 

  2. Pereira S, Vieira B, Maio T et al (2020) Susac’s syndrome: an updated review. Neuro-Ophthalmol 44:355–360. https://doi.org/10.1080/01658107.2020.1748062

    Article  Google Scholar 

  3. Sauma J, Rivera D, Wu A et al (2020) Susac’s syndrome: an update. Br J Ophthalmol bjophthalmol. https://doi.org/10.1136/bjophthalmol-2019-315597

    Article  Google Scholar 

  4. Dörr J, Krautwald S, Wildemann B et al (2013) Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol 9:307–316. https://doi.org/10.1038/nrneurol.2013.82

    Article  PubMed  Google Scholar 

  5. Ben David C, Sharif K, Watad A et al (2017) Susac Syndrome: A Rare Cause of a Confusional State. Isr Med Assoc J IMAJ 19:651–653

    PubMed  Google Scholar 

  6. Feresiadou A, Eriksson U, Larsen H-C et al (2014) Recurrence of Susac syndrome following 23 years of remission. Case Rep Neurol 6:171–175. https://doi.org/10.1159/000362868

    Article  PubMed  PubMed Central  Google Scholar 

  7. Susac JO, Murtagh FR, Egan RA et al (2003) MRI findings in Susac’s syndrome. Neurology 61:1783–1787. https://doi.org/10.1212/01.wnl.0000103880.29693.48

    Article  CAS  PubMed  Google Scholar 

  8. Agamanolis DP, Prayson RA, Asdaghi N et al (2019) Brain microvascular pathology in Susac syndrome: an electron microscopic study of five cases. Ultrastruct Pathol 43:229–236. https://doi.org/10.1080/01913123.2019.1692117

    Article  PubMed  Google Scholar 

  9. Jarius S, Kleffner I, Dörr JM et al (2014) Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation 11:46. https://doi.org/10.1186/1742-2094-11-46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gross CC, Meyer C, Bhatia U et al (2019) CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nat Commun 10:5779. https://doi.org/10.1038/s41467-019-13593-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Susac JO (1994) Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 44:591–593. https://doi.org/10.1212/wnl.44.4.591

    Article  CAS  PubMed  Google Scholar 

  12. Rennebohm RM, Asdaghi N, Srivastava S, Gertner E (2020) Guidelines for treatment of Susac syndrome – An update. Int J Stroke 15:484–494. https://doi.org/10.1177/1747493017751737

    Article  PubMed  Google Scholar 

  13. Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324. https://doi.org/10.1002/art.37754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Picardo S, So K, Venugopal K (2020) Anti-TNF-induced lupus in patients with inflammatory bowel disease. JGH Open Open Access J Gastroenterol Hepatol 4:507–510. https://doi.org/10.1002/jgh3.12291

    Article  Google Scholar 

  15. Kristensen LB, Lambertsen KL, Nguyen N et al (2021) The role of non-selective TNF inhibitors in demyelinating events. Brain Sci 11:38. https://doi.org/10.3390/brainsci11010038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Patwala K, Crump N, De Cruz P (2017) Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-219481

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mohan N, Edwards ET, Cupps TR et al (2004) Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31:1955–1958

    CAS  PubMed  Google Scholar 

  18. Palucka AK, Blanck J-P, Bennett L et al (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102:3372–3377. https://doi.org/10.1073/pnas.0408506102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kemanetzoglou E, Andreadou E (2017) CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 17:36. https://doi.org/10.1007/s11910-017-0742-1

    Article  PubMed  PubMed Central  Google Scholar 

  20. Louis M, Rauch J, Armstrong M, Fitzcharles M-A (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557–2562

    CAS  PubMed  Google Scholar 

  21. Hoffman GS, Merkel PA, Brasington RD et al (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304. https://doi.org/10.1002/art.20300

    Article  CAS  PubMed  Google Scholar 

  22. Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatol Oxf Engl 41:1303–1307. https://doi.org/10.1093/rheumatology/41.11.1303

    Article  CAS  Google Scholar 

  23. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808–810

    PubMed  Google Scholar 

  24. Buelens T, Ossewaarde-van Norel J, de Boer JH et al (2020) Evaluation of tumor necrosis factor inhibitor therapy in susac syndrome. Retina 40:581–590. https://doi.org/10.1097/IAE.0000000000002466

    Article  CAS  PubMed  Google Scholar 

  25. Fernando SL, Boyle T, Smith A, Parratt JDE (2020) The successful use of infliximab in a relapsing case of Susac’s syndrome. Case Rep Neurol Med 2020:1–6. https://doi.org/10.1155/2020/9317232

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital of Strasbourg, No. 1, Avenue Molière, 67200, Strasbourg, France

    Stanislas Demuth, Thomas Bogdan, Laurent Kremer, Livia Lanotte, Nicolas Collongues, Jérôme de Seze & Kévin Bigaut

Authors
  1. Stanislas Demuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Bogdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurent Kremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Livia Lanotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Collongues
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jérôme de Seze
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kévin Bigaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kévin Bigaut.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Consent to participate

Informed consent was obtained from the patient included in the study.

Ethical approval

This case report has been approved by the ethics committee of the university hospital of Strasbourg and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Demuth, S., Bogdan, T., Kremer, L. et al. Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab. J Neurol 269, 3347–3350 (2022). https://doi.org/10.1007/s00415-021-10922-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-021-10922-x

Search

Navigation